⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Cellipont Bioservices and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Cellipont Bioservices
↗The Woodlands, Texas, USA
Cellipont Bioservices is a specialized Contract Development and Manufacturing Organization (CDMO) focused on cell therapy and gene-modified cell therapy products. The company provides end-to-end services including process development, analytical development, cGMP manufacturing, and regulatory support to help biopharmaceutical companies transition from early clinical stages to commercial supply.
Headquartered in The Woodlands, Texas, the company operates a 76,000 sq. ft. state-of-the-art manufacturing facility designed to meet stringent regulatory requirements. Cellipont has established itself as a key partner in the advanced therapeutics space, collaborating with various biotech firms to accelerate the development of innovative treatments such as CAR-T and iPSC-derived therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2002
Ownership:private
Status:operating
FUNDING
Stage:Private Equity-Backed
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (CDMO)
Modalities:Cell therapy, CAR-T, iPSC, Exosomes
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Soter Bio (RNA/LNP manufacturing integration), Applied StemCell (iPSC-derived cell therapy development), Marker Therapeutics (cGMP manufacturing for MT-601), Secretome Therapeutics (cGMP manufacturing for STM-01), Wugen (CAR-T cell therapy manufacturing)
COMPETITION
Position:Challenger
Competitors:Excellos
LEADERSHIP
Key Executives:
Darren Head - CEO
LINKS
Website:cellipont.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Cellipont Bioservices. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.